Sunday, August 20, 2017

Latuda Has the Greatest Commercial Potential Among New Agents Entering the Bipolar Disorder Drug Market Through 2022

October 14, 2013 by  
Filed under Depression

BURLINGTON, Mass., Oct. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Dainippon Sumitomo Pharma/Sunovion/Takeda ...

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!